Describe in detail, the clinical pharmacology support studies (not the single ascending dose study, multiple ascending dose study, Phase II or Ill studies) that are typically done for
a small molecule entity (SME), but NOT for a monoclonal antibody (MAB), giving the rationale for why they are not required to be done for the antibody.